1
|
Tanimura K, Nakano Y, Sato-Otsubo A, Yamasaki K, Fukushima H, Tanaka M, Yoshioka T, Okita H, Kunihiro N, Sakamoto H, Inoue T, Fujisaki H, Hara J. Radiation-induced osteosarcoma in a patient with DICER1 syndrome. Pediatr Blood Cancer 2022; 69:e29782. [PMID: 35593689 DOI: 10.1002/pbc.29782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2021] [Revised: 04/21/2022] [Accepted: 04/22/2022] [Indexed: 11/12/2022]
Affiliation(s)
- Kazuki Tanimura
- Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.,Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Yoshiko Nakano
- Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.,Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Aiko Sato-Otsubo
- Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Kai Yamasaki
- Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan
| | - Hiroko Fukushima
- Department of Diagnostic Pathology, Osaka City Juso Hospital, Osaka, Japan.,Department of Diagnostic Pathology, Osaka City General Hospital, Osaka, Japan
| | - Mio Tanaka
- Department of Pathology, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
| | - Takako Yoshioka
- Department of Pathology, National Center for Child Health and Development, Tokyo, Japan
| | - Hazime Okita
- Division of Diagnostic Pathology, Keio University, Tokyo, Japan
| | - Noritsugu Kunihiro
- Division of Pediatric Neurosurgery, Osaka City General Hospital, Osaka, Japan
| | - Hiroaki Sakamoto
- Division of Pediatric Neurosurgery, Osaka City General Hospital, Osaka, Japan
| | - Takeshi Inoue
- Department of Diagnostic Pathology, Osaka City General Hospital, Osaka, Japan
| | - Hiroyuki Fujisaki
- Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan
| | - Junichi Hara
- Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan
| |
Collapse
|
2
|
Wang F, Zhuang L, Liang J, Li L, Wang H, Tang J, Zeng J, Liu W. Treatment and prognosis of pleuropulmonary blastoma: A single-center report of 31 cases. Pediatr Pulmonol 2022; 57:2237-2243. [PMID: 35510654 DOI: 10.1002/ppul.25930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/07/2022] [Accepted: 04/10/2022] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Pleuropulmonary blastoma (PPB) is a very rare and highly aggressive neoplasm occurring in children, mostly under 6 years of age. We assessed the clinical characteristics, treatment modalities, treatment outcomes, and prognostic factors affecting survival in patients with PPB treated at our institution over a 10-year period to improve the prognosis. METHODS From November 2008 to November 2019, 31 children (21 boys and 10 girls) with a median age of 30 months (ranging, 22 days to 54 months) were treated at our institution. Here we describe the patient characteristics, treatment modalities, and treatment outcomes. The Kaplan-Meier method was used to estimate the progression-free survival (PFS) and overall survival (OS). Log-rank test was performed for comparison between groups. RESULTS Three children were lost to follow-up and two were dead due to postoperative complications. Of the 26 patients included in the follow-up, 16 PPB patients displayed tumor-free survival. The 5-year PFS and OS were 60.4% and 60.1% respectively. By stratified statistical analysis, the 5-year PFS and OS of type I PPB were 100%, while those of type III PPB were 43.7% and 43%, respectively. The 5-year PFS and OS of complete tumor resection were 76.5% and 75.6%, respectively, while those with tumor residue were 31.3%. The 5-year PFS and OS combined with chemotherapy were 62.2% and 61.6%, respectively, while those without chemotherapy were 0%. CONCLUSIONS PPB is an aggressive neoplasm. The main factors related to the prognosis of PPB are pathological type, tumor resection degree, and postoperative adjuvant therapy.
Collapse
Affiliation(s)
- Fenghua Wang
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| | - Linwei Zhuang
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| | - Jianhua Liang
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| | - Le Li
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| | - Hui Wang
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| | - Jue Tang
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| | - Jiahang Zeng
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| | - Wei Liu
- Department of Thoracic Surgery, Guangzhou Women and Children's Medical Centre, Guangzhou, Guangdong, China
| |
Collapse
|
3
|
Shim J, Reisner A, Esiashvili N, Rapkin L, Olson T. Intraventricular topotecan in the successful treatment of recurrent CNS pleuropulmonary blastoma. Pediatr Blood Cancer 2022; 69:e29529. [PMID: 34913589 DOI: 10.1002/pbc.29529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Revised: 11/16/2021] [Accepted: 11/24/2021] [Indexed: 11/12/2022]
Abstract
Pleuropulmonary blastoma (PPB) is a rare pediatric tumor of the pleura and pulmonary mesenchyme, associated with pathogenic germline DICER1 mutations. Although the most common site of metastasis is the central nervous system (CNS), patients with CNS metastasis have dismal outcome. We report a case of a patient presenting with type II PPB and intracranial and bone metastases. We describe a multimodal therapy approach and highlight the use of intraventricular topotecan for isolated CNS recurrence. In addition, a new pathogenic germline mutation heterozygous for the c.1234delT of DICER1 was identified. Patient remains in remission 3 years after recurrence.
Collapse
Affiliation(s)
- Jenny Shim
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.,Aflac Cancer and Blood Disorders Center at the Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Andrew Reisner
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.,Department of Neurosurgery, Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Natia Esiashvili
- Department of Radiation Oncology, Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia, USA
| | - Louis Rapkin
- Department of Oncology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Thomas Olson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.,Aflac Cancer and Blood Disorders Center at the Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| |
Collapse
|
4
|
Sparber-Sauer M, Tagarelli A, Seitz G, Sorg B, Bien E, Bel-Ami T, Pourtsidis A, Lopez Almaraz R, Koscielniak E, Ferrari A, Orbach D, Bisogno G. Children with progressive and relapsed pleuropulmonary blastoma: A European collaborative analysis. Pediatr Blood Cancer 2021; 68:e29268. [PMID: 34486213 DOI: 10.1002/pbc.29268] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 06/26/2021] [Accepted: 07/14/2021] [Indexed: 01/14/2023]
Abstract
BACKGROUND Children with progressive (PD) or relapsed disease (RD) of pleuropulmonary blastoma (PPB) type II/III are known to have a very poor outcome. METHODS A retrospective review of children registered in national and European databases and trials (2000-2018) with diagnosis of PPB type II/III and PD or RD was performed. RESULTS A total of 35 patients with PPB were analysed: patients with PD (n = 9) and RD (n = 26). Patients experienced PD at the median age of 3.9 years [range, 0.5-17.8] despite surgery, chemotherapy (CHT, n = 9) and radiotherapy (RT, n = 1) with a median time to progression of 0.58 years [range, 0.02-1.27] from diagnosis. All of them died. Patients suffered from RD at the median age of 4.3 years [1.7-15.1], median delay to relapse 1.03 years [range, 0.03-2.95]. RD occurred locally (n = 12), combined (n = 1) and in metastatic sites (n = 13): central nervous system (n = 11) and unspecified site (n = 2). Patients were treated with salvage CHT (n = 20), surgery (n = 10) ± RT (n = 10). After a median follow-up of 4.2 years [range, 2.1-14.6], a second complete remission (CR) was achieved in nine out of 26 patients. Patients were alive in the second CR (n = 6), in the third CR (n = 1), in partial remission (n = 2) and lost of follow-up (n = 1). Five-year event-free survival (EFS) and overall survival (OS) for patients with RD were both 37% (±19, CI 95%). Local therapy (surgery, RT) had a favourable impact on OS (p = 0.03 and 0.02, respectively). CONCLUSIONS Cure of patients with RD of PPB type II/III with multimodal treatment is possible but rare. Progressive PPB is fatal and patients need new treatment options.
Collapse
Affiliation(s)
- Monika Sparber-Sauer
- Klinikum der Landeshauptstadt Stuttgart gKAäR, Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Stuttgart, Germany
| | - Arianna Tagarelli
- Division of Pediatric Hematology and Oncology, Department of Women's and Children's Health, University of Padua, Padua, Italy
| | - Guido Seitz
- Department of Pediatric Surgery, University Children's Hospital, Marburg, Germany
| | - Benjamin Sorg
- Klinikum der Landeshauptstadt Stuttgart gKAäR, Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Stuttgart, Germany
| | - Ewa Bien
- Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdańsk, Poland
| | - Tal Bel-Ami
- Pediatric Hematology-Oncology Unit, Kaplan Medical Center, Rehovot, Israel
| | | | - Ricardo Lopez Almaraz
- Pediatric Oncology and Hematology Unit, Cruces University Hospital, Barakaldo, Spain
| | - Ewa Koscielniak
- Klinikum der Landeshauptstadt Stuttgart gKAäR, Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Stuttgart, Germany.,Department of Pediatric Hematology and Oncology University, Children's Hospital, Tuebingen, Germany
| | - Andrea Ferrari
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Daniel Orbach
- SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, Université PSL, Paris, France
| | - Gianni Bisogno
- Division of Pediatric Hematology and Oncology, Department of Women's and Children's Health, University of Padua, Padua, Italy
| | | |
Collapse
|
5
|
Chong AS, Han H, Albrecht S, Weon YC, Park SK, Foulkes WD. DICER1 syndrome in a young adult with pituitary blastoma. Acta Neuropathol 2021; 142:1071-1076. [PMID: 34677675 DOI: 10.1007/s00401-021-02378-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 10/14/2021] [Accepted: 10/15/2021] [Indexed: 12/23/2022]
|
6
|
Bisogno G, Sarnacki S, Stachowicz-Stencel T, Minard-Colin V, Ferrari A, Godzinski J, Gauthier-Villars M, Bien E, Hameury F, Helfre S, Schneider DT, Reguerre Y, Almaraz RL, Janic D, Cesen M, Kolenova A, Rascon J, Martinova K, Cosnarovici R, Pourtsidis A, Ben-Ami T, Roganovic J, Koscielniak E, Schultz KAP, Brecht IB, Orbach D. Pleuropulmonary blastoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer 2021; 68 Suppl 4:e29045. [PMID: 33826235 PMCID: PMC9813943 DOI: 10.1002/pbc.29045] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Revised: 03/15/2021] [Accepted: 03/16/2021] [Indexed: 01/11/2023]
Abstract
Pleuropulmonary blastoma (PPB) is a rare cancer occurring mainly during early childhood and often associated with germline DICER1 mutations. It is classified by the macroscopic appearance into three interrelated clinico-pathologic entities on a developmental continuum. Complete tumor resection is a main prognostic factor and can be performed at diagnosis or after neoadjuvant treatment that includes chemotherapy and in some cases radiotherapy. Optimal modalities of neo- or adjuvant treatments can be challenging taking into account potential long-term toxicities in this young population. This paper presents the recommendations for diagnosis and treatment of children and adolescents with PPB elaborated by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) within the European Union-funded project PARTNER (Paediatric Rare Tumours Network - European Registry).
Collapse
Affiliation(s)
- Gianni Bisogno
- Hematology-Oncology Division, Department of Women’s and Children’s Health, Padova University Hospital, Italy
| | - Sabine Sarnacki
- Department of Pediatric Surgery, Hôpital Necker-Enfants Malades, Université de Paris, Paris, France
| | | | - V Minard-Colin
- Department of Paediatric and Adolescent Oncology, INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Andrea Ferrari
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
| | - Jan Godzinski
- Department of Pediatric Surgery, Marciniak Hospital, Wroclaw, Poland
| | - Marion Gauthier-Villars
- Department of Genetics, Institut Curie, Paris, France; Paris Sciences Lettres Research University, Paris, France
| | - Ewa Bien
- Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Poland
| | - Frederic Hameury
- Department of Pediatric Surgery, Hôpital Femme Mère Enfant, Lyon, France
| | | | | | - Yves Reguerre
- Pediatric Hematology-Oncology Department, Centre Hospitalier Universitaire, Saint Denis de La Réunion, France
| | - Ricardo Lopez Almaraz
- Pediatric Oncology- Hematology Unit, University Hospital of Cruces, Barakaldo-Bizkaia, Spain
| | - Dragana Janic
- Department of Hematology and Oncology, University Children's Hospital, University of Belgrade, Belgrade, Serbia
| | - Maja Cesen
- University Medical Centre, Ljubljana, Slovenia
| | - Alexandra Kolenova
- Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases and Comenius University Bratislava, 833 40 Bratislava, Slovakia
| | - Jelena Rascon
- Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Kata Martinova
- Department of Hematology and Oncology, University Clinic for Children`s Diseases, Medical Faculty, Ss Cyril and Methodius University of Skopje, Republic of North Macedonia
| | - Rodica Cosnarovici
- Oncology Institute ”Prof. dr. Ion Chiricuta”, Oncopediatric Department, Cluj-Napoca, Romania
| | - Apostolos Pourtsidis
- Oncology Department, P. and A. Kyriakou Children's Hospital, 115 27 Athens, Greece
| | - Tal Ben-Ami
- Pediatric Hematology Unit, Kaplan Medical Center, Rehovot, Israel
| | - Jelena Roganovic
- Department of Pediatrics, Clinical Hospital Center Rijeka, University of Rijeka, Croatia
| | - Ewa Koscielniak
- Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart - Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart, Germany
| | - Kris Ann P. Schultz
- International PPB/DICER1 Registry, Cancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA
| | - Ines B. Brecht
- Pediatric Hematology and Oncology, Children’s Hospital, Eberhard-Karls-Universitaet Tuebingen, Germany
| | - Daniel Orbach
- SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with cancer), Institut Curie, PSL University, Paris, France
| |
Collapse
|
7
|
Ferguson MJ, Ivanovich J, Stansell P, Vik TA, Helvie AE, Schmitt MR, Schultz KA, Dehner LP, Renbarger JL, Marshall MA. Previously unreported somatic variants in two patients with pleuropulmonary blastoma with metastatic brain recurrence. Pediatr Blood Cancer 2021; 68:e28825. [PMID: 33258270 PMCID: PMC9677809 DOI: 10.1002/pbc.28825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 11/06/2020] [Accepted: 11/09/2020] [Indexed: 11/05/2022]
Affiliation(s)
- Michael J Ferguson
- Indiana University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Indianapolis, IN 46202
| | - Jennifer Ivanovich
- Indiana University School of Medicine, Department of Genetics, Indianapolis, IN 46202
| | - Paige Stansell
- Indiana University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Indianapolis, IN 46202
| | - Terry A Vik
- Indiana University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Indianapolis, IN 46202
| | - Amy E Helvie
- Department of Pharmacy, Riley Hospital for Children at IU Health, Indianapolis, IN 46202
| | - Morgan R Schmitt
- Indiana University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Indianapolis, IN 46202
| | - Kris Ann Schultz
- Children’s Minnesota, Cancer and Blood Disorders, International PPB/DICER1 Registry, Minneapolis, MN 55404
| | - Louis P Dehner
- Children’s Minnesota, Cancer and Blood Disorders, International PPB/DICER1 Registry, Minneapolis, MN 55404,Lauren V. Ackerman Laboratory of Surgical Pathology, Washington University Medical Center, St. Louis, MO 63110
| | - Jamie L Renbarger
- Indiana University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Indianapolis, IN 46202
| | - Mark A Marshall
- Indiana University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Indianapolis, IN 46202
| |
Collapse
|